Shots:
BPOM has approved Qdenga for the prevention of dengue disease caused by any serotype in patients aged 6 to 45yrs. The therapy is expected to be available in the coming months
The approval was based on an ongoing P-III (TIDES) trial to evaluate Qdenga in ~20000 healthy children & adolescents aged 4 to 16yrs. with dengue endemic across Asia & Latin America. The results showed continued overall protection against dengue illness & hospitalization @3yrs. after vaccination regardless of prior dengue exposure, was well tolerated with no safety risks
Qdenga is currently under regulatory review for the prevention of dengue in children and adults in the EU and dengue-endemic countries outside the EU
Ref: Businesswire | Image: Takeda
